WIPO logo
Mobile | Deutsch | English | Español | Français | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

国際・国内特許データベース検索
World Intellectual Property Organization
検索
 
閲覧
 
翻訳
 
オプション
 
最新情報
 
ログイン
 
ヘルプ
 
自動翻訳
1. (WO2009094426) 13,13-DIMETHYL-DES-C,D ANALOGS OF 1ALPHA, 25-DIHYDROXY-19-NOR-VITAMIN D3 COMPOUNDS AND TOPICAL COMPOSITION DOSAGE FORMS AND METHODS OF TREATING SKIN CONDITIONS THEREOF
国際事務局に記録されている最新の書誌情報   

Translation翻訳: 原文 > 日本語
国際公開番号:    WO/2009/094426    国際出願番号:    PCT/US2009/031663
国際公開日: 30.07.2009 国際出願日: 22.01.2009
IPC:
C07C 35/17 (2006.01), C07C 401/00 (2006.01), A61K 31/047 (2006.01), A61P 17/06 (2006.01), A61P 17/00 (2006.01), A61P 35/00 (2006.01), C07F 7/18 (2006.01)
出願人: WISCONSIN ALUMNI REASEARCH FOUNDATION [US/US]; 614 Walnut Street Madison, WI 53705 (US) (米国を除く全ての指定国).
DELUCA, Hector, F. [US/US]; (US) (米国のみ).
CLAGETT-DAME, Margaret [US/US]; (US) (米国のみ).
PLUM, Lori, A. [US/US]; (US) (米国のみ).
SICINSKI, Rafal, R. [PL/PL]; (PL) (米国のみ).
PLONSKA-OCYPA, Katarzyna [PL/PL]; (PL) (米国のみ).
NIEVES, Nirca, J. [US/US]; (US) (米国のみ).
GRZYWACZ, Pawel [PL/US]; (US) (米国のみ)
発明者: DELUCA, Hector, F.; (US).
CLAGETT-DAME, Margaret; (US).
PLUM, Lori, A.; (US).
SICINSKI, Rafal, R.; (PL).
PLONSKA-OCYPA, Katarzyna; (PL).
NIEVES, Nirca, J.; (US).
GRZYWACZ, Pawel; (US)
代理人: MEARA, Joseph, P.; FOLEY & LARDNER LLP 150 East Gilman Street Post Office Box 1497 Madison, WI 53701-1497 (US)
優先権情報:
61/022,696 22.01.2008 US
発明の名称: (EN) 13,13-DIMETHYL-DES-C,D ANALOGS OF 1ALPHA, 25-DIHYDROXY-19-NOR-VITAMIN D3 COMPOUNDS AND TOPICAL COMPOSITION DOSAGE FORMS AND METHODS OF TREATING SKIN CONDITIONS THEREOF
(FR) ANALOGUES 13,13-DIMÉTHYL-DES-C,D DE COMPOSÉS DE 1-ALPHA, 25-DIHYDROXY-19-NOR-VITAMINE D3 ET FORMES POSOLOGIQUES DE COMPOSITIONS TOPIQUES ET PROCÉDÉS DE TRAITEMENT D'ÉTATS PATHOLOGIQUES DE LA PEAU
要約: front page image
(EN)13,13-Dimethyl-flfes-C,D analogs of lα,25-dihydroxy-19-nor-vitamin D3 compounds and topical composition dosage forms thereof, and methods of treating skin conditions thereof. Exemplary active pharmaceutical ingredients include (lR,3R)-5-[(E)-(S)-11'-hydroxy-5',5',7',11'-tetramethyl-dodec-2'-enylidene]-2-metylene-cyclohexane-l,3-diol, (lR,3R)-5-[(Z)-(S)-11 '-hydroxy-5',5',7',11'-tetramethyl-dodec-2'-enylidene]-2-metylene-cyclohexane-l,3-diol, (lR,3R)-5-[(E)-(R)-l 1 '-hydroxy-5',5',7',11 '-tetramethyl-dodec-2'-enylidene]-2-metylene- cyclohexane-l,3-diol, and lR,3R)-5-[(Z)-(R)-11'-hydroxy-5',5',7',11'-tetramethyl-dodec-2'- enylidene] -2-metylene-cyclohexane- 1,3 -diol.
(FR)L'invention porte sur des analogues 13,13-diméthyl-des-C,D de composés de lα,25-dihydroxy-19-nor-vitamine D3 et sur des formes posologiques de compositions topiques de ceux-ci, ainsi que sur des procédés de traitement d'états pathologiques de la peau par ceux-ci. Des exemples d'ingrédients pharmaceutiques actifs comprennent le (1R,3R)-5-[(E)-(S)-11'-hydroxy- 5',5',7',11'-tétraméthyl-dodéc-2'-énylidène]-2-méthylènecyclohexane-l,3-diol, le (1R,3R)-5-[(Z)-(S)-11'-hydroxy-5',5',7',11'-tétraméthyl-dodéc-2'-énylidène]-2-méthylènecyclohexane-l,3-diol, le (1R,3R)-5-[(E)-(R)-l 1'-hydroxy-5',5',7',11'-tétraméthyl-dodéc-2'-énylidène]-2-méthylènecyclohexane-l,3-diol et le (1R,3R)-5-[(Z)-(R)-11'-hydroxy-5',5',7',11'-tétraméthyl-dodéc-2'- énylidène]-2-méthylènecyclohexane-1,3-diol.
指定国: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
アフリカ広域知的所有権機関(ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
ユーラシア特許庁(EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
欧州特許庁(EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
アフリカ知的所有権機関(OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
国際公開言語: English (EN)
国際出願言語: English (EN)